Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Edetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.48 |
| ▸ | CA4 known ✓ | P22748 | 8/20 | 0.40 |
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.35 |
| ▸ | CA1 known ✓ | P00915 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | EYA2 | O00167 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL3374424 | 1.00 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL30259751 | 0.97 | KDM4E (0.77) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL352497 | 0.97 | KDM4E (0.70) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL3835316 | 0.97 | KDM4E (0.76) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL42427 | 0.97 | KDM4E (0.76) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL906 | 0.97 | KDM4E (0.76) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL44287 | 0.97 | KDM4E (0.76) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL5315227 | 0.97 | KDM4E (0.68) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL243998 | 0.94 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL1090576 | 0.94 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230276819-A1 | IRON FORTIFIED TEA-BASED BEVERAGE | GLOBAL LOAN AGENCY SERVICES GMBH (DE) | 2023-09-07 | — | — | US | claimed |
| US-20160221233-A1 | Method of forming a fibrous product | TEKNOLOGIAN TUTKIMUSKESKUS VTT OY (FI) | 2016-08-04 | — | — | US | claimed |
| EP-3044253-A1 | METHOD OF FORMING A FIBROUS PRODUCT | Teknologian tutkimuskeskus VTT Oy (FI) | 2016-07-20 | — | — | EP | claimed |
| WO-2015036659-A1 | METHOD OF FORMING A FIBROUS PRODUCT | TEKNOLOGIAN TUTKIMUSKESKUS VTT (FI) | 2015-03-19 | — | — | WO | claimed |
| EP-0777495-B1 | STABLE, AQUEOUS ALFA INTERFERON SOLUTION FORMULATIONS | SCHERING CORP (US) | 2000-07-19 | — | — | EP | claimed |
| EP-0443007-B1 | AN EXTERNAL ANALGESIC LOTION AND METHOD OF MAKING | IVY JEFFERY W (US) | 1995-03-08 | — | — | EP | claimed |
| EP-0443007-A4 | AN EXTERNAL ANALGESIC LOTION AND METHOD OF MAKING | — | 1993-03-03 | — | — | EP | claimed |
| US-5124320-A | An external analgesic lotion containing active ingredients of camphor and menthol and method of making such lotion | AU PHARMACEUTICALS, INC. | 1992-06-23 | — | — | US | claimed |
| EP-0443007-A1 | AN EXTERNAL ANALGESIC LOTION AND METHOD OF MAKING. | IVY JEFFERY W (US) | 1991-08-28 | — | — | EP | claimed |
| US-5043307-A | Steaming, dealuminizing | MOBIL OIL CORP. (US) | 1991-08-27 | — | — | US | claimed |
| US-5013726-A | External analgesic lotion containing active ingredients of methyl salicylate and camphor and menthol and method of making such lotion | AU PHARMACEUTICALS, INC. | 1991-05-07 | — | — | US | claimed |
| WO-1991004010-A1 | AN EXTERNAL ANALGESIC LOTION AND METHOD OF MAKING | IVY JEFFERY W (US) | 1991-04-04 | — | — | WO | claimed |
| US-4876411-A | DEALUMINIZATION | MOBIL OIL CORPORATION (US) | 1989-10-24 | — | — | US | claimed |
| US-4093560-A | REMOVING ALUMINUM FROM ALUMINOSILICATES BY COMPLEXING WITH AN AMMONIUM OR ALKALI METAL SALT | MOBIL OIL CORPORATION (US) | 1978-06-06 | — | — | US | claimed |
| US-20260109872-A1 | Ink Jet Ink Composition And Ink Jet Recording Method | SEIKO EPSON CORP (JP) | 2026-04-23 | — | — | US | disclosed |
| US-20260071089-A1 | Ink Jet Composition Set | SEIKO EPSON CORP (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4285947-B1 | METHOD FOR PRODUCING COATED MEDICAL DEVICE | TORAY INDUSTRIES (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-4312947-A | SERIAL PASSAGE IN CAT KIDNEY CELLS | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1982-01-26 | — | — | US | disclosed |
| US-4093560-A | REMOVING ALUMINUM FROM ALUMINOSILICATES BY COMPLEXING WITH AN AMMONIUM OR ALKALI METAL SALT | MOBIL OIL CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
| US-4044158-A | MEAT, WATER, SUGAR, VEGETABLE PROTEIN, ANTIMYCOTIC | THE QUAKER OATS COMPANY (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109872-A1 | Ink Jet Ink Composition And Ink Jet Recording Method | COPE, EED, VCL | ACE 3423/4885CA4 3356/4885CA2 4233/4885 |
| US-20260071089-A1 | Ink Jet Composition Set | CA1, CA3, CA12 | ACE 4577/4885CA4 11/4885CA2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.